<DOC>
	<DOCNO>NCT02607696</DOCNO>
	<brief_summary>This Phase I , open-label , randomized trial evaluate single-dose pharmacokinetics Zolpidem orodispersible tablet two different dosage ( 1.75 mg 3.50 mg ) . Sample size 48 participant , male female , age 18 years-old . Primary objective evaluate pharmacokinetics Zolpidem orodispersible tablet two different dosage ( 1.75 mg 3.50 mg ) , secondary objective evaluate safety tolerability investigational product . Participants admit period 36 hour , investigational product administer , blood sample , pre-determined time period , collect pharmacokinetics . Primary endpoint obtain pharmacokinetics parameter . Additionally , safety assess adverse event occurrence laboratory exams evaluation .</brief_summary>
	<brief_title>Pharmacokinetics Zolpidem Orodispersible Tablet</brief_title>
	<detailed_description />
	<mesh_term>Zolpidem</mesh_term>
	<criteria>Male female study participant , age 18 yearsold ; woman pregnant breastfeed Body mass index ( BMI ) great equal 19 less equal 28.75 Kg/m2 Good health condition without significant disease , accord best medical judgement , accord protocol requirement study evaluation : medical history , blood pressure heart rate measurement , physical examination , electrocardiogram ( ECG ) complementary laboratory test Ability understand nature objective trial , include risk adverse event ; willingness cooperate researcher proceed accord study requirement , shall confirm Informed Consent Form signature . Known hypersensitivity investigational product ( Zolpidem ) chemically related compound ; history serious adverse reaction hypersensitivity drug History presence hepatic gastrointestinal disease , condition interferes drug absorption , distribution , excretion metabolism Chronic therapy drug , except oral contraceptive History hepatic , kidney , lung , gastrointestinal , epileptic , hematologic psychiatric disease ; hypotension hypertension , etiology , require pharmacological treatment ; history myocardial infarction , angina and/or heart failure Electrocardiographic finding , investigator criterion , recommend study participation Deviations screen laboratory result consider clinically relevant researcher Smoking Intake 5 cup coffee tea per day Unusual food habit , e.g. , vegetarian History drug alcohol addiction excessive alcohol consumption ( &gt; 35 g/day ) Use regular medication within 2 week prior study enrollment use medication within one week prior study enrollment , except oral contraceptive case , base drug 's metabolite 's halflife , complete elimination assume Hospitalization reason 8 week trial Treatment , within 6 month trial , drug know wellestablished toxic potential major organ Participation experimental research administration experimental drug within 6 month trial Donation loss 450 mL blood within 3 month trial 3 donation ( woman ) /4 donation ( men ) blood within 12 month trial Any condition , accord investigator 's best judgement , prevents subject participate trial Pregnancy , labor miscarriage 12 week admission predict date .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>